Natural killer cells in non-hematopoietic malignancies

Por Desbois, Mélanie, Rusakiewicz, Sylvie, Locher, Clara, Zitvogel, Laurence, Chaput, Nathalie
Publicado em 2012

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

Por Chaput, Nathalie, Flament, Caroline, Locher, Clara, Desbois, Mélanie, Rey, Annie, Rusakiewicz, Sylvie, Poirier-Colame, Vichnou, Pautier, Patricia, Le Cesne, Axel, Soria, Jean-Charles, Paci, Angelo, Rosenzwajg, Michelle, Klatzmann, David, Eggermont, Alexander, Robert, Caroline, Zitvogel, Laurence
Publicado em 2013

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Por Hannani, Dalil, Vétizou, Marie, Enot, David, Rusakiewicz, Sylvie, Chaput, Nathalie, Klatzmann, David, Desbois, Melanie, Jacquelot, Nicolas, Vimond, Nadège, Chouaib, Salem, Mateus, Christine, Allison, James P, Ribas, Antoni, Wolchok, Jedd D, Yuan, Jianda, Wong, Philip, Postow, Michael, Mackiewicz, Andrzej, Mackiewicz, Jacek, Schadendorff, Dirk, Jaeger, Dirk, Korman, Alan J, Bahjat, Keith, Maio, Michele, Calabro, Luana, Teng, Michele WL, Smyth, Mark J, Eggermont, Alexander, Robert, Caroline, Kroemer, Guido, Zitvogel, Laurence
Publicado no Cell Res (2015)

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Por Hannani, Dalil, Vétizou, Marie, Enot, David, Rusakiewicz, Sylvie, Chaput, Nathalie, Klatzmann, David, Desbois, Melanie, Jacquelot, Nicolas, Vimond, Nadège, Chouaib, Salem, Mateus, Christine, Allison, James P, Ribas, Antoni, Wolchok, Jedd D, Yuan, Jianda, Wong, Philip, Postow, Michael, Mackiewicz, Andrzej, Mackiewicz, Jacek, Schadendorff, Dirk, Jaeger, Dirk, Korman, Alan J, Bahjat, Keith, Maio, Michele, Calabro, Luana, Teng, Michele WL, Smyth, Mark J, Eggermont, Alexander, Robert, Caroline, Kroemer, Guido, Zitvogel, Laurence
Publicado no Cell Res (2015)